잠시만 기다려 주세요. 로딩중입니다.

10일 혼합 요법의 헬리코박터 파일로리 1차 치료 제균율

First-line Helicobacter pylori Eradication Rate of the 10-day Hybrid Therapy

박정훈, 김동우, 최정완, 김승영, 정성우, 현종진, 정영걸, 구자설, 임형준, 이상우,
소속 상세정보
박정훈 ( Park Jeong-Hun ) - Korea University Ansan Hospital Department of Internal Medicine
김동우 ( Kim Dong-Woo ) - Korea University Ansan Hospital Department of Internal Medicine
최정완 ( Choe Jung-Wan ) - Korea University Ansan Hospital Department of Internal Medicine
김승영 ( Kim Seung-Young ) - Korea University Ansan Hospital Department of Internal Medicine
정성우 ( Jung Sung-Woo ) - Korea University Ansan Hospital Department of Internal Medicine
현종진 ( Hyun Jong-Jin ) - Korea University Ansan Hospital Department of Internal Medicine
정영걸 ( Jung Young-Kul ) - Korea University Ansan Hospital Department of Internal Medicine
구자설 ( Koo Ja-Seol ) - Korea University Ansan Hospital Department of Internal Medicine
임형준 ( Yim Hyung-Joon ) - Korea University Ansan Hospital Department of Internal Medicine
이상우 ( Lee Sang-Woo ) - Korea University Ansan Hospital Department of Internal Medicine

Abstract


Background/Aims: To improve the eradication rate of a first-line therapy for Helicobacter pylori infection, alternate regimens such as sequential, concomitant, and hybrid therapies have been tried. The aim of this study was to evaluate the eradication rate of the 10-day hybrid therapy as a first-line therapy.Materials and

Methods: This retrospective study enrolled 124 patients from the Korea University Ansan Hospital between April 2016 and December 2019. The 10-day hybrid therapy comprised 5 days of dual therapy (proton pump inhibitor [PPI] standard dose and amoxicillin 1 g, twice daily) followed by 5 days of quadruple therapy (PPI, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, twice daily). We compared the 10-day hybrid therapy with the 10-day concomitant therapy comprising PPI, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, twice daily. Eradication was assessed by a 13C-urea breath test or gastroscopic biopsy at least 4 weeks after treatment completion.

Results: The eradication rates of the 10-day hybrid and concomitant therapies were 74.2% (46/62) and 67.7% (42/62), respectively, in the intention-to-treat (ITT) analysis and 88.5% (46/52) and 82.4% (42/51), respectively, in the per-protocol (PP) analysis. There was no significant difference in the eradication rates between the two groups in the ITT (P=0.429) and PP analysis (P=0.380). Adverse events developed in 75.0% and 70.6% of patients in the hybrid and concomitant groups, respectively, but there was no significant difference (P=0.615).

Conclusions: The 10-day hybrid therapy can be an option for a first-line therapy of Helicobacter pylori infection.

키워드

Anti-bacterial agents; elicobacter pylori; Therapy

원문 및 링크아웃 정보

등재저널 정보